期刊名称：THERAPEUTIC ADVANCES IN DRUG SAFETY ISSN： 2042-0986 出版频率： Continuous publication 出版社： SAGE PUBLICATIONS LTD, 1 OLIVERS YARD, 55 CITY ROAD, LONDON, ENGLAND, EC1Y 1SP   出版社网址： https://journals.sagepub.com/ 期刊网址： https://journals.sagepub.com/home/tawa 影响因子： 3.842 主题范畴： PHARMACOLOGY & PHARMACY 变更情况： 期刊简介(About the journal)    投稿须知(Instructions to Authors)    编辑部信息(Editorial Board)    About the journal Aims and Scope Therapeutic Advances in Drug Safety delivers the highest quality peer-reviewed  open access original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies pertaining to the safe use of drugs in patients. The journal has a strong clinical and pharmacological focus and is aimed at an international audience of clinicians and researchers in drug safety, providing an online forum for rapid dissemination of recent research and perspectives in this area.  The journal is dedicated to publishing clinical research. We do not publish preclinical research, including basic laboratory research and animal studies. Review articles include expert opinion/perspective reviews (including single-drug and drug class reviews), narrative reviews and therapeutic area reviews. Systematic reviews, meta-analyses, postmarketing and health economic and pharmacoeconomic reviews are also welcomed. The appropriate EQUATOR Network reporting guidelines should be followed (e.g. CONSORT for randomized, controlled trials and PRISMA for systematic reviews/meta-analyses). The journal conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment as a condition of consideration for publication. The trial registry name and URL, and registration number must be included at the end of the abstract.  The journal adheres to a blind review process in which the reviewer's name is routinely withheld from the author unless the reviewer requests a preference for their identity to be revealed. Manuscripts are reviewed by at least two referees.   Instructions to Authors Manuscript Submission Guidelines: Therapeutic Advances in Drug Safety This Journal is a member of the Committee on Publication Ethics. This Journal recommends that authors follow the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals formulated by the International Committee of Medical Journal Editors (ICMJE). All articles are listed on PubMed. Please read the guidelines below then visit the Journal’s submission site http://mc.manuscriptcentral.com/tads to upload your manuscript. Please note that manuscripts not conforming to these guidelines may be returned. Remember you can log in to the submission site at any time to check on the progress of your paper through the peer review process. Only manuscripts of sufficient quality that meet the aims and scope of Therapeutic Advances in Drug Safetywill be reviewed. As part of the submission process you will be required to warrant that you are submitting your original work, that you have the rights in the work, that you are submitting the work for first publication in the Journal and that it is not being considered for publication elsewhere and has not already been published elsewhere, and that you have obtained and can supply all necessary permissions for the reproduction of any copyright works not owned by you. Therapeutic Advances in Drug Safety may accept submissions of papers that have been posted on pre-print servers; please alert the Editorial Office when submitting (contact details are at the end of these guidelines) and include the DOI for the preprint in the designated field in the manuscript submission system. Authors should not post an updated version of their paper on the preprint server while it is being peer reviewed for possible publication in the journal. If the article is accepted for publication, the author may re-use their work according to the journal's author archiving policy. If your paper is accepted, you must include a link on your preprint to the final version of your paper. Citing preprints is permitted if no peer reviewed version of the article has been published. Open Access Article Processing Charge (APC) Article Types 3.1 Titles 3.2 Keywords 3.3 Abstracts 3.4 Plain language summaries Editorial policies 4.1 Peer review policy 4.2 Authorship 4.3 Acknowledgements 4.4 Funding 4.5 Declaration of conflicting interests 4.6 Research ethics and patient consent 4.7 Clinical trials 4.8 Reporting guidelines 4.9 Data Publishing policies 5.1 Publication ethics 5.2 Contributor's publishing agreement Preparing your manuscript 6.1 Formatting 6.2 Artwork, figures and other graphics 6.3 Supplementary material 6.4 Reference style 6.5 English language editing services Submitting your manuscript 7.1 ORCID 7.2 Information required for completing your submission  7.3 Permissions On acceptance and publication 8.1 SAGE Production 8.2 Online First publication 8.3 Access to your published article  8.4 Promoting your article Further information   Editorial Board Hide All Editor-in-Chief Arduino Mangoni MD, MRCP (UK), FRACP, FRCP (London), FRCP (Glasgow), FRCP (Edinburgh) Flinders University, Australia Managing Editor Elena Conroy SAGE Publications Ltd, UK Associate Editors Joris Berwaerts MD J&J Pharmaceutical Research & Development, USA Matthew P. Doogue BSc, MBCHB, DipPaed, FRACP Univeristy of Otago Christchurch, New Zealand Vicki Osborne PhD, MSc, BSc Drug Safety Research Unit, Southampton, UK Roy Soiza MB, ChB. MRCP NHS Grampian, Aberdeen, UK Stephen Waring BMedSci, MB, BCh, BAO, PhD York Hospitals NHS Trust, UK Editorial Board Anna Birna Almarsdóttir PdD, MS, MSc University of Copenhagen, Copenhagen, Denmark Andrew Bate PhD Pfizer Inc., New York, NY, USA Christopher Beer MB, BS, GradCertHPEd, PhD, FRACP Royal Perth Hospital, Perth, WA, Australia J Simon Bell PhD Monash University, Melbourne, Australia Phil Berry MBBS, Mphil Independent Pharmaceutical Consultant, Geneva, Switzerland Kin-Wei Chan MD, ScD, FISPE National Taiwan University, Taipei, Taiwan Antonio Cherubini MD, PhD IRCCS INRCA, Ancona, Italy Bernard Cheung MA, MB BChir, PhD, MRCP, FRCP, FCP, FHKCP, FHKAM (Medicine) The University of Hong Kong, Hong Kong Claire Davies Medicines and Healthcare Products Regulatory Agency, London, UK Jacques Descotes MD, PharmD, PhD Lyon University Hospitals (HCL), Lyon, France Alex Dodoo B.Pharm, MSc, PhD, FPSGH, FPCPharm University of Ghana Medical School, Accra, Ghana Stanley Garbus MD, MPH Garbus Consulting, West New York, NJ, USA Phil Hannaford MBChB University of Aberdeen, Aberdeen, UK Manfred Hauben MD, PhD New York, NY, USA Sarah Hilmer BScMed, MBBS, FRACP, PhD Royal North Shore Hospital, St Leonards, NSW, Australia Paul Jansen MD, PhD University Medical Centre, Utrecht, Netherlands Jimmy Jose MPharm, PhD School of Pharmacy, University of Nizwa, Oman Neil Kaplowitz MD University of Southern California, Los Angeles, CA, USA Stephen Leslie BSc, MB ChB, PhD, FRCP Raigmore Hospital, Inverness, UK Sunny Linnebur Pharm.D, FCCO, BCPS, CGP Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Denver, Colorado, USA Mary J Macleod BSc, MBChB, PhD, FRCP University of Aberdeen, Aberdeen, UK Jennifer Martin MA, MBBS, PhD University of Queensland, Brisbane, QLD, Australia Glenn Matfin MB, ChB National Health Service, London, UK Patricia Mcgettigan MD, FRCPI, FRACP Hull York Medical School, Hull/York, UK James McLay University of Aberdeen, Aberdeen, UK Christoph Meier PhD, MSc University Hospital Basel, Basel, Switzerland Yola Moride PhD, FISPE University of Montreal, Montreal, QC, Canada Vicky Parikh MD, PPH Mid-Atlantic Medical Research Centers, Hollywood, MD, USA Emilio Perucca University of Pavia, Pavia, Italy Philip Pierce MD Johnson & Johnson Pharmaceutical Research and Development, Titusville, NJ, USA Munir Pirmohamed BChB, MRCO, PhD, FRCP, FBPharmacolS University of Liverpool, Liverpool, UK Thomas M. Polasek BSc, BPharm, PhD Flinders University, Adelaide, SA, Australia Amrit Ray MD, MBA Johnson & Johnson Pharmaceuticals Group, Titusville, NJ, USA Michael Rieder MD, PhD Childrens Hospital of W. Ontario, London, ON, Canada Luis Rios-Nogales MD, PhD Rational Vaccines, Boston, MA, USA Greg Roberts Bpharm Repatriation General Hospital, Daw Park, SA, Australia Allen Root University of South Florida, USA Dietrich Rothenbacher MD, PhD University of Ulm, Ulm, Germany Andrew Rowland Flinders University, Australia Leo Russo MS, PhD Shire Pharmaceuticals, Wayne, PA, USA Mohammed Salahudeen BPharm, PharmD, MBA, PhD, AFHEA School of Pharmacy and Pharmacology, University of Tasmania, Hobart, Australia Marco Sardella, PharmD, EEA QPPV ADIENNE Pharma & Biotech, Monza e Brianza, Italy Carmelo Scarpignato MD, DSc, FRCP, FACP, FACG University of Parma, Parma, Italy Michael Schachter Schachter BSc, MB, FRCP Imperial College London, UK Rashmi Shah BSc, MBBS, FRCP, FRCP, MD, FFPM, HonFBPhS Rashmi Shah Consultancy Ltd, Gerrards Cross, UK Michael Sorich Flinders University, Australia Sara Tommasi, PhD Flinders University, Adelaide, Australia Scott Twaddell BMedSc, BMed, GCClinTox, FRACP University of Newcastle, Newcastle, NSW, Australia Allen Vaida PharmD, BSc Institute of Safe Medication Practices, Horsham, PA, USA Tjeerd Van Staa MD, PhD, MA, MSc Medicines and Healthcare Products Regulatory Agency, London, UK David Williams PhD, FRCP Royal College of Surgeons, Eire, Ireland Richard Woodman PhD, MBiostats, MMedSco, BSc Flinders Centre for Epidemiology and Biostatistics, Flinders University, Adelaide, Australia Jane Woolley PhD Medicines and Healthcare products Regulatory Agency, USA Patient Advisory Board Tina Aswani Omprakash Patient Advocate Trishna Bharadia Patient Advocate, Maidenhead, UK Anisha Gangotra Patient Advocate, High Wycombe, UK Dominique Hamerlijnck MPhil, MBA European Patients' Academy (EUPATI), Amsterdam, Netherlands Sheila Khawaja The World Alliance of Pituitary Organizations (WAPO), Monfalcone, Italy Paola Kruger European Patients' Academy (EUPATI), Rome, Italy